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The primary goal was to study the influence of adipocyte number and volume, 
inflammation, insulin resistance, and genetic factors on indicators of liver injury, 
surrogate marker of non alcoholic fatty liver disease (NAFLD). The secondary goal was 
to explore the occurrence of NAFLD and its relationship with variations in liver function 
biomarkers. The first objective was to determine the association of plasma levels of 
monocyte chemoattractant protein-1 (MCP-1) with omental adipocyte number, insulin 
resistance and circulating concentrations of liver injury markers, alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST) in unrelated baboons. Significant 
associations of MCP-1 with other measured traits were established. The second objective 
was to examine if adiposity-related parameters are under genetic influence and to 
evaluate their genetic correlations with AST in pedigreed baboons. Adipocyte volume 
and number, body weight and plasma AST were heritable. Genetic correlations between 
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adiposity-related phenotypes and AST were significant. A genome wide scan yielded a 
strong signal for adipocyte volume on chromosome 6. The third aim was to explore the 
genetic factors that influence variations in plasma levels of γ glutamyl transferase (GGT) 
and albumin (ALB), and to evaluate their genetic correlations with cardiovascular risk 
factors in pedigreed baboons. Significant linkages for GGT and albumin were identified 
on chromosome 20_22 and chromosome 10, respectively. Genetic correlations between 
ALB and cardiovascular risk factors were significant. No statistically significant 
associations were found between GGT and cardiovascular-related phenotypes. The fourth 
objective was to investigate the prevalence of NAFLD and its association with altered 
liver protein levels in unrelated baboons. The influence of weight and insulin resistance 
on the occurrence of NAFLD was inconclusive. Significant relationships between the 
variations in plasma levels of liver injury biomarkers and severity of the disease could not 
be established. In conclusion, the first three studies provided observational and genetic 
evidence of a relationship between liver function markers and adiposity-related factors in 
baboons. However, the results of the fourth study do not provide conclusive evidence to 
suggest that body weight and insulin resistance play a significant role in the development 
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Chapter 1  
Review of Literature 
 
 
The National Health and Nutrition Examination Survey (1999-2002) estimates 
that more than 60 million adults (≥20years ) are obese [Body mass index (BMI) ≥ 30 
kg/m
2
] (CDC, 2004). The prevalence of fatty liver disease in the adult population of the 
United States is 31 % (Browning et al., 2004); and is higher in the obese (Bellentani et 
al., 1994). Hepatic fat deposition in obese and insulin resistant individuals is called non-
alcoholic fatty liver (NAFL) because alcohol use is not an etiologic factor (Festi et al., 
2004). In non-alcoholic fatty liver, insulin resistance is believed to be the primary reason 
for the initiation of fat accretion in the liver cells (Charlton, 2004). Fatty liver is 
characterized histologically by macrovesicular steatosis, or accumulation of large lipid 
droplets in more than 5% of hepatocytes (Neuschwander-Tetri and Caldwell, 2003). This 
disease has clinical significance because it progresses to hepatocellular inflammation 
(steatohepatitis), which leads to liver cirrhosis (Cortez-Pinto & Camilo, 2004). 
Hepatic steatosis is accompanied by altered circulating levels of liver proteins that 
are biomarkers of liver injury. However, genetic factors also are known to influence liver 
function markers (Bathum, 2001), as well as obesity-related factors (Comuzzie, 2002). It 
is hypothesized in the present project that common genes might affect both traits. In this 
study the contribution of indicators of liver injury, inflammation, insulin resistance, and 






1.1 Aims  
 
1) To investigate the association of plasma levels of monocyte chemoattractant protein -
1 (MCP-1) with an indicator of insulin sensitivity and circulating levels of liver 
function markers in baboons. 
Hypothesis: Increased plasma levels of MCP-1 are associated with reduced insulin 
sensitivity and elevated plasma concentrations of liver enzymes. 
2) To conduct univariate and bivariate analyses for omental adipocyte volume and 
number and plasma levels of aspartate aminotransferase in baboons. 
Hypothesis: There is a significant contribution of genes on omental adipocyte volume 
and number and plasma aspartate aminotransferase. A common genetic denominator 
may be responsible for relationship between these phenotypes. 
3) To identify quantitative trait loci (QTLs) for circulating levels of γ glutamyl 
transferase (GGT) and albumin (ALB). 
Hypothesis: There is a substantial effect of specific chromosomal regions on plasma 
levels of GGT and ALB and on the genetic relationship between the traits related to 
liver function and cardiovascular disease. 
4) To explore the occurrence of NAFLD and determine its relationship with markers of 
liver injury in baboons. 
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Hypothesis: The incidence of NAFLD will be higher in obese versus non-obese 
baboons. Also, markers of liver injury will be positively related to the extent of liver 
damage due to the disease. 
 
1.2 Background  
 
Hepatic steatosis was considered an aftermath of excessive alcohol consumption in 
the past, but now it is observed in obese individuals with minimal alcohol intake 
(Bradbury, 2006). Based on the 2000 census report (Census, 2001), 30 million obese 
adults in the United States are estimated to have steatosis (Angulo, 2002). Non-alcoholic 
fatty liver disease (NAFLD) is the most common liver pathology affecting the population 
of the Western countries (Falck-Ytter et al., 2001). This disease encompasses histological 
changes such as fatty liver, steatohepatitis, fibrosis and cirrhosis (Matteoni et al., 1999). 
The prevalence of hepatic steatosis and non-alcoholic steatohepatitis (NASH) in the 
general population is 20-30 % and 2-3%, respectively (Yu and Keeffe, 2002).The 
incidence of hepatic steatosis is far greater (50-70%) in obese individuals (Wanless and 
Lentz, 1990). Of these, about 20-30 % will develop NASH and 2-5 % will have cirrhosis 
(Reid, 2001). Furthermore, NAFLD has been implicated in the pathogenesis of 
hepatocellular carcinoma (Bugianesi et al., 2002).This proposal will focus on non-
alcoholic fatty liver due to obesity and insulin resistance. Body mass index (Angulo et al., 
1999) and insulin resistance (Marchesini et al., 1999) are independent predictors of the 
degree of triglyceride accumulation in the liver.  
Although the mechanism leading to accumulation of liver triglycerides is unclear, it 
is postulated that the genesis of fatty liver is initiated by proinflammatory cytokines that 
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lead to insulin resistance (Choi & Diehl, 2005). It is believed that in obese individuals 
insulin resistance and inflammation are connected closely since obesity is characterized 
by a chronic state of inflammation. In the past adipocytes were thought to be a 
contributor to the pool of circulating immunomodulatory proteins. However, an 
investigation by Weisberg et al. (2003) has suggested that inflammation associated with 
obesity may be due to macrophage infiltration into adipose tissue. A transplantation study 
in transgenic mice showed that the macrophage population within the adipose tissue is 
derived from bone marrow (Weisberg et al., 2003). Curat et al. (2004) also have provided 
evidence of increased chemotaxis of monocytes into the adipose tissue, increasing the 
resident population of macrophages in the fat depots. 
It is hypothesized (Arner, 2005) that changes in the fat cell size creates trauma 
within the fat depot. This trauma leads to the induction of MCP-1 (Juge-Aubry et al., 
2005). It is postulated that MCP 1, a chemokine, is responsible for attracting monocytes 
into the visceral and subcutaneous fat depots of humans (Brunn et al., 2005). Within the 
monocytes nuclear factor kappa B (NF-κB), a proinflammatory transcription factor, is 
activated by tumor necrosis factor α (TNF-α) derived from adipocytes (Ghanim et al., 
2004). Nuclear factor κB complex consists of two subunits, p65 (RelA) and p50, that are 
bound to a nuclear factor Kappa-B inhibitor (IκBα). This antagonist keeps the complex 
inactive in the cytoplasm (May and Ghosh, 1997) . Phosphorylation of IκBα by kinase 
IKKβ allows NFκB complex to translocate into the nucleus and turn on the transcription 
of inflammatory genes such as TNF-α and interleukin 6 (IL-6) (Bonizzi and Karin, 
2004). However, NFκB is in turn stimulated by TNF-α, inducing a continuous cycle of 
inflammatory signals (Wellen and Hotamisligil, 2003). The pro-inflammatory cytokines 
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TNF-α and IL-6 from the monocytes that infiltrate the adipose tissue cause local insulin 
resistance by impeding the insulin-signaling pathway (Vettor et al., 2005). In summary, 
all of the above factors contribute to insulin resistance, the proposed metabolic basis for 
the occurrence of fatty liver in obese individuals.  
Insulin resistance leads to the release of free fatty acids from the adipocytes into the 
circulation (Bugianesi et al., 2005). Normally, insulin inhibits the action of hormone 
sensitive lipase in the fat cells, thus, limiting the conversion of triglycerides to free fatty 
acids (Festi et al, 2004). When insulin action within the fat cells is impaired , the 
inhibitory effect of this protein on hormone sensitive lipase is removed; thereby, 
increasing the release of free fatty acids from fat stores into the blood (Arner, 2005). Both 
elevated fatty acids levels, and hyperinsulinemia (Yu and Ginsberg, 2005) characterize 
insulin resistance. One of the key features of steatosis is increased delivery of free fatty 
acids to the liver. Sources of these free fatty acids are lipolysis from subcutaneous and 
visceral adipocytes (Medina et al., 2004). However, the impact of non-esterified fatty 
acids from visceral adipocytes is the most significant. These acids from the central 
adipose depots drain directly into the liver via the portal vein (Kabir et al., 2005). In a 
study by Hsieh & Yoshinaga (1995) the prevalence of fatty liver was greater in normal 
weight individuals with a high waist to hip ratio, as compared to individuals with a low 
ratio [30.5% vs. 15.7%]. 
In hepatocytes high insulin levels increase free fatty acid synthesis, suppress free 
fatty acid oxidation and reduce triglyceride export (Sanyal, 2005). The mechanism by 
which insulin augments triglyceride accumulation in the liver is via up regulation of the 
transcription of Sterol Regulatory
 









fatty acids (Richardson et al., 
2005). Increased fatty acid concentration within the liver inhibits carnitine palmitoyl 
transferase-1 (CPT-1), the enzyme that transports fatty acids into the mitochondria for 
oxidation (Browning and Horton, 2004). In addition, insulin reduces triglyceride export 
from the liver in animal models by decreased secretion of VLDL, a triglyceride 
containing lipoprotein assembled in the liver (Au et al., 2004). This inhibitory effect is 
mediated by SREBP 1-c (Sato et al., 1999).  
Many methods can be employed to diagnose NAFLD but liver biopsy is the only 
procedure that can truly distinguish the different stages of this disease (Hubscher S, 
2004). The extent of histological changes associated with inflammation can be graded 
accurately with a biopsy (Adams and Talwalkar, 2006). Non-invasive methods used to 
detect the severity of liver damage due to fatty acid deposition include ultrasound (Joy et 
al., 2003), computer tomography (Limanond et al., 2004), magnetic resonance imaging 
(Saaseh et al., 2002) and liver injury markers (Schindhelm et al., 2006). Yet none of these 
techniques has the sensitivity and specificity as great as that of liver biopsy (Sanyal A, 
2002). However, it is not feasible to perform liver biopsy for all patients suspected to 
have NAFLD due to cost, invasiveness, and risk associated with biopsy. Therefore, this 
study uses liver function marker as surrogate of NAFLD. Thus, the first aim of this 
research project is to investigate the association of plasma levels of monocyte 
chemoattractant protein -1 (MCP-1) with indicator of insulin sensitivity and circulating 
levels of liver function markers in baboons. 
Monocyte chemotactic protein (MCP-1/CCL2) also is called the small inducible 
cytokine A2 (SCYA2), as well as monocyte chemotactic and activating factor (MCAF). 
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Endothelial cells, vascular smooth muscle cells and monocytes produce this low 
molecular weight (8 kDa) polypeptide on exposure to inflammatory stimuli (Becker, 
2005). This peptide mediates its action by binding to its specific receptor, CC chemokine 
receptor 2 (CCR2) (Neels and Olefsky, 2006). Chemokines such as MCP-1 inhibit 
adipocyte differentiation and increase leptin production, acting as anti-adipogenic agents 
(Gerhardt et al., 2001). 
Dahlman et al. (2005) showed that obese individuals have increased expression of 
chemokines in their adipocytes. The development of insulin resistance in mature fat cells 
may contribute to increased MCP-1 concentration (Sartipy & Loskutoff, 2003). It has 
been shown recently that reduction in MCP-1 mRNA levels improves insulin sensitivity 
in human adipose tissue (Di Gregorio et al., 2005). Patients with low insulin sensitivity 
were treated with thialzolidinedione, an antidiabetic drug, for ten weeks. The treatment 
ameliorated insulin resistance by decreasing MCP-1 mRNAs in the adipose tissue by 
50%. A concurrent reduction in macrophage numbers also was observed. This proposal 
will investigate the genetic factors that control the expression of MCP-1. This knowledge 
will increase the understanding of insulin resistance related to obesity that results in 
hepatic steatosis. 
Liver pathology leads to the release of their constituents into the circulation. The 
liver proteins whose plasma levels are abnormal in the event of hepatic injury are alanine 
aminotransferase, asparate amniotransferase, gamma-glutamyl transpeptidase and 
albumin. Other liver function aberrations such as elevated alkaline phosphate, bilirubin 
and lactate dehydrogenase are not evident in patients with a fatty liver (Charlton, 2004). 
The enzyme, alanine aminotransferase, catalyzes the reversible conversion of L-alanine 
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and alpha-ketoglutarate to L-glutamate and pyruvate. The transfer of an amino group 
from glutamate to oxaloaceate forms alpha-ketoglutarate and aspartate. This reaction is 
promoted by the second enzyme, asparate amniotransferase. The third marker is the 
catalyst gamma-glutamyl transpeptidase, which assists in the transfer of the glutamyl 
moiety cleaved from one protein or peptide to another. Finally, albumin, a negative acute-
phase protein which constitutes about half of the serum protein, acts as a carrier for 
various intrinsic and extrinsic compounds including fatty acids. It also participates in 
stabilizing extracellular fluid volume. 
Although other organs produce ALT and AST, liver houses the highest 
concentration of these aminotransferases. Low amounts of AST can be found in the heart, 
brain and red blood cells, whereas, skeletal muscle and kidney contains small 
concentrations of both the enzymes (Wroblewski, 1958). Similarly, GGT is present in 
miniscule quantities in biliary epithelial cells, renal tubules, intestine and the pancreas 
besides hepatocytes (Giannini et al., 2005). Liver is the major site for albumin 
production, and its reduced blood levels indicate impaired liver synthetic activity 
(Tessari, 2003).  
In the Western world, NAFLD is the most common reason for altered levels of 
hepatic proteins according to a survey conducted by the NHANES III (Harrison et al., 
2002).
.
 In a study by Chang et al., (2007) elevated ALT was estimated to be an 
independent predictor of NAFLD in healthy men. A significant correlation between ALT 
and hepatic fat accumulation, as determined by magnetic resonance spectroscopy, was 
established by Westerbacka et al. (2004) in both non-diabetic men and women. In 
humans, obesity and insulin resistance are known to be positively associated with raised 
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levels of plasma AST and GGT (Marchesini, 2005). In patients who lost weight after a 
laparoscopic gastric banding surgery the plasma levels of AST and GGT showed a 
marked reduction, which was parallel to improvement in histological features of fatty 
liver disease (Dixon et al., 2006). Angulo et al. (2007) found that serum albumin is one of 
the independent indicators of advanced stages of NAFLD. These results imply that 
hepatic proteins provide relevant information about hepatic pathology related to obesity 
and reduced insulin sensitivity.  
In this research proposal it is hypothesized that genetic components may be 
responsible for variations in adipocyte volume and number as well as levels of liver 
enzymes. The second aim of this dissertation is to conduct univariate and bivariate 
analyses for omental adipocyte volume and number and plasma levels of aspartate 
aminotransferase in baboons. Adipose tissue expansion during weight gain can occur 
either by hypertrophy or hyperplasia, or both. In other words, enlargement of the fat 
depots could be due to increase in fat cell volume and/or size (Hausman et al., 2001). The 
balance between lipogeneis and lipolysis determines the adipocyte volume, and fat cell 
number is dictated by the equilibrium between the proliferation or differentiation and 
apoptosis (Avramm et al., 2005).  
In adults initiation of obesity is believed to be distinctly because of fat cell 
hypertrophy. However, it is theorized that these cells have limited capacity to expand 
(Kawada et al., 2001). After reaching a critical mean volume the enlarged cell undergo 
death due to stress (Monteiro et al., 2006). After which fat depots grow due to 
hyperplasia (Coppack, 2005). The dead adipocytes activate inflammatory signaling 
pathways, subsequently, attracting macrophages into the adipose tissues to clear cellular 
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debris (Weisberg et al., 2003). The cytokines released by the macrophages compromise 
the insulin sensitivity of the fat cells (Cinti et al., 2005). Ultimately, inflammation- 
induced insulin resistance results in NAFLD.  
It is postulated that NAFLD and cardiovascular disease might be associated since they 
share the same risk factors such as central obesity and compromised insulin sensitivity. 
Fatty liver disease is known to exacerbate insulin resistance as well as lead to 
dyslipidaemia, both of which contribute to atherosclerosis (Adiels et al., 2006). In 
addition, later stages of this hepatic condition are related to increased oxidative stress. 
The reactive oxygen species generated due to fatty acid oxidation can induce endothelial 
damage (Madamanchi et al., 2005). A recent observational study reported that NAFLD is 
a predictor of cardiovascular disease in healthy men and women. The relationship 
between NAFLD and prospective occurrence of CVD was significant even after inclusion 
of known cardiovascular risk factors in the multivariate model (Hamaguchi et al., 2007). 
Many epidemiological studies have shown strong associations between mildly elevated 
liver enzymes and increased CVD incidence (Wannamethee et al., 1995; Ruttmann et al., 
2005; Ioannou et al., 2006; Schindhelm et al., 2007). These findings warrant an 
investigation into the influence of genetic factors on both these obesity related co-
morbidities. Therefore, the third aim of this study is to identify quantitative trait loci 
(QTLs) for circulating levels of γ glutamyl transferase (GGT) and albumin (ALB). 
The fourth aim of this project is to explore the occurrence of NAFLD and determine 
its relationship with markers of liver injury in baboons. Baboons will be the animal 
model used to explore the relationship between the phenotypes of interest. This primate is 
a well-established model for studying genetic of polygenic diseases (Cai et al., 2004; 
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Tejero et al., 2004) because baboon and human chromosomal structure are 96% 
homologous (Cole et al., 2003). Based on this information, a 10-cM linkage map for 
baboons using human microstatellite markers has been formulated (Rogers et al., 2000). 
A subset of the baboons in the population at Southwest Foundation for Biomedical 
Research (SFBR) in San Antonio, Texas have developed obesity (10%) and become 
insulin resistant (4%), in spite of the same controlled housing and diet. Most of these 
animals exhibit increased abdominal fat deposition, which is associated with insulin 
resistance and fatty liver (Comuzzie et al., 2003). Obesity related phenotypes such as 
weight (kg), fat mass (kg), fat free mass (kg) and leptin (ng/ml) are known to be highly 
heritable in these baboons and are almost identical to that reported in humans (Comuzzie 
& Allison, 1998). Thus, these baboons are ideal to study the effect of genetics on 
variability of liver function. Futhermore, baboons have been used in the study of alcohol-
induced fatty liver (Lieber, 1975)
 
and the effects of inflammation on hepatocytes (Lue et 
al., 1981).  
In conclusion, the goal of this project is to establish the association between 
adipocyte volume and number, inflammation, insulin resistance and markers of liver 
damage. The secondary purpose is to identify the quantitative trait loci influencing the 
adiposity related traits and biomarkers of liver function In addition; this study also will 
explore the genetic relationship between surrogate markers of NAFLD, fat cell volume 




Chapter 2  
Association of Monocyte Chemoattractant Protein-1 with Adipocyte Number, 




Monocyte chemoattractant protein-1 (MCP-1) is an inflammatory chemokine 
known to induce adipocyte dedifferentiation and insulin resistance. Both reduced insulin 
sensitivity and obesity have been implicated in the pathogenesis of non-alcoholic fatty 
liver disease (NAFLD). The objective of this paper is to determine the association of 
plasma levels of MCP-1 with omental adipocyte number, insulin resistance and the 
circulating concentrations of liver injury markers, alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST).  
Fasting plasma from 43 baboons were assayed for MCP-1, insulin, glucose, ALT, 
and AST by standard procedures. Adipocyte number and volume were measured via 
biopsies of omental adipose tissue. The homeostatic model assessment method (HOMA) 
was used to estimate systemic insulin resistance. Mean weights of males and females 
were 32.42 ± 1.6 kg and 19.22 ± 0.8 kg. Sex and age adjusted correlations were 
significant for MCP-1 with adipocyte number (r = -0.42; p = 0.01), adipocyte volume (r = 
0.38; p= 0.02), HOMA (r = 0.45; p = 0.004), ALT (r = 0.46; p = 0.03) and AST (r = 0.45; 
p = 0.03). These results suggest that MCP-1 is related with adipocyte dedifferentiation 





In obesity adipocytes expand in size due to the deposition of triglycerides 
(Greenberg and Obin, 2006). However, this expansion may be limited. Chen et al. (2006) 
hypothesized that excessive hypertrophy of the fat cells might create a hypoxic 
environment within the adipose tissue. Consequently, this reduced availability of oxygen 
could lead to adipocyte death (Neels and Olefsky, 2006) which may then trigger 
macrophage infiltration to clear the cellular debris (Cinti et al., 2005). It is believed that 
monocyte chemoattractant protein-1 (MCP -1), a chemokine released by adipocytes, is 
responsible for attracting monocytes into these injured fat depots (Christiansen et al., 
2005).  
The expression and secretion of MCP-1 is known to be elevated during obesity in 
both mice (Takahashi et al. 2003) and humans (Bruun et al., 2005). MCP-1 mediates its 
action by binding to its specific receptor CC chemokine receptor 2 (CCR2) (Charo et al., 
1994). In a recent study, obese mice lacking CCR2 had low macrophage concentrations 
in adipose tissue (Weisberg et al., 2006). In addition, MCP-1 is believed to induce the 
dedifferentiation of adipocytes, which might result in obesity- related disorders due to 
ectopic fat deposition (Tsuchiya et al., 2006). The expression of MCP-1 is higher in 
visceral, as compared to subcutaneous, adipose tissue (Bruun et al., 2005). This protein 
impairs insulin-stimulated glucose uptake in adipocytes, resulting in insulin resistance 
(Sartipy and Loskutoff, 2003). Thus, it is postulated that MCP-1 may play an integral role 
in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) (Kanda et al., 2006).  
Two major risk factors of NAFLD are visceral obesity and insulin resistance 
(Angulo P, 2002). In the pathogenesis of NAFLD in overweight and obese individuals, 
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insulin and excessive free fatty acids from insulin-resistant omental adipose tissue drain 
directly into the liver via the portal vein. In the liver, insulin up-regulates the conversion 
of unesterified fatty acids to triacylgycerols by the activation of sterol regulatory binding 
protein -1C (Kotani et al., 2004). Simultaneously, insulin reduces triglyceride export 
from the liver by decreased secretion of VLDL, a triglyceride-containing lipoprotein 
assembled in the liver (Au et al., 2004). This results in lipid accumulation in the 
hepatocytes that further triggers a cascade of necroinflammatory changes such as 
steatohepatitis, fibrosis and finally, cirrhosis (Day and James, 1998).  
Ultimately, complications of NAFLD can lead to end stage liver disease and 
hepatocellular carcinoma (Neuschwander-Tetri BA, 2007).  
At present, the gold standard for diagnosing fatty liver disease is a biopsy (Brunt, 
2005). However, two biochemical markers of hepatic injury, plasma alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) will be used in this study 
as non-invasive surrogates for NAFLD (Suzuki et al., 2006). 
The purpose of this paper is to evaluate the importance of inflammation in the 
pathogenesis of NAFLD, using overweight and obese baboons as a model of chronic 
inflammation. We hypothesize that increased circulating levels of MCP-1 are associated 
with fewer mature adipocytes. This inflammatory molecule might also result in insulin 
resistance and elevated circulating levels of liver function markers due to subsequent 
liver injury caused by fat deposition.  





Forty three (31 females, 12 males) unrelated baboons (Papio hamadrayas 
cynocephalus) were included in this study The baboon colony is maintained at the Southwest 
National Primate Research Center located at the Southwest Foundation for Biomedical 
Research (SFBR) in San Antonio, TX, USA. These animals are gang-housed and fed a low fat, 
standard monkey chow diet ad libitum (Harlan Teklad 15% monkey diet, 8715, Indianapolis, 
IN).  
Sampling and Analyses 
Animals were fasted overnight (12 hours) and sedated with ketamine before collection 
of blood samples. Body weights were measured on a calibrated electronic scale (GSE, Chicago, 
IL). A total of 10 ml of blood was drawn from the antecubital vein in heparin tubes. Plasma 
was obtained by centrifugation at 2000 x g for 10 minutes and was stored in aliquots at –80 
0
C 
for future analysis. The Institutional Animal Care and Use Committee of the SFBR approved 
all procedures. Assays for ALT and AST were conducted by standard laboratory techniques 
using an Alfa Wasserman ACE clinical chemistry instrument (West Cladwell, NJ). Glucose 
was analyzed on an Analox spectrophotometer by the glucose oxidase method. Insulin and 
MCP-1 was measured by chemiluminescence in a Luminex 100 with endocrine multiplex 
immunoassay (Linco Research, Inc). Insulin resistance was calculated by the homeostatic 
model assessment (HOMA) method (Matthews et al., 1985). Biopsies of omental adipose tissue 
were taken and adipocyte number and volume per gram of tissue was analyzed by methods 
previously described by Lewis et al. (1986). All samples whose replicates varied >5% 




Descriptive statistics and other analyses were conducted using SPSS (SPSS Inc., 
Chicago, IL; V 10.0). Results are expressed as mean (standard error of mean). Student’s t- test 
was used to determine the differences between sexes. All variables, other than sex and age, 
were log transformed to obtain a Gaussian distribution. Linear regression was performed, 
controlling for the effect of age and sex to estimate the association of plasma MCP-1 with 
omental adipocyte number and volume, HOMA scores, and plasma ALT and AST. Residual 
analysis, using Cook’s distance and leverage coefficients, was conducted to analyze the effect 
of any point on the estimated regression (Sokal and Rohlf, 1994).  
2.4 Results 
 
Table 2.1 illustrates the traits analyzed in the baboons. The study population was 
comprised of more than twice as many females as males. The mean body weight of 
females was lower than that of males. Female body weights ranged from 14 kg to 32 kg 
and that of the males from 28 kg to 47 kg. Females were significantly older and had 
reduced concentrations of plasma MCP-1 as compared to males. Adipocyte number and 
volume, HOMA and plasma levels of ALT were not substantially different between the 
sexes. However, differences between the circulating concentrations of AST approached 
statistical significance.  
After adjusting for age and sex, plasma MCP-1 was negatively associated with 
adipocyte number (Figure 2.1) and positively associated with adipocyte volume (r = 0.38; 
p= 0.02), HOMA (Figure 2.2), ALT (Figure 2.3) and AST (Figure 2.4).  




This is the first study to demonstrate that plasma levels of MCP-1 are negatively 
associated with omental adipocyte number and positively associated with adipocyte 
volume, HOMA and liver function markers in baboons. 
In adipocyte dedifferentiation loss of mature adipocyte phenotype occurs through 
the suppression of two transcription factors, CCAAT/enhancer binding protein α 
(C/EBPα) and peroxisome proliferator- activated receptor γ (PPARγ) (Schaffler et al., 
2006). These factors act in concert to regulate the expression of adipogenic genes 
required to maintain mature fat cells in a differentiated state (Kirkland et al., 2002). 
Sartipy and Loskutoff (2003) have suggested that MCP-1 may cause a reduction in the 
number of fat cells by reducing the mRNA expression of PPARγ. In addition, Nadler et 
al. (2000) have reported that adipose tissue from obese mice exhibit a decreased number 
of C/EBPα and PPARγ transcripts. The down regulation of these adipogenic genes might 
be due to obesity-related inflammation.  
It is believed that fewer mature adipocytes lead to over expansion of existing fat 
cells, causing stress within the adipose tissue and stimulating the inflammatory system 
(Heilbronn et al., 2004). Our data suggests that obesity-related inflammation may lead to 
an abnormal adipocyte life cycle, which reduces the number of lipid-bearing mature 
adipocytes and finally, lead to other metabolic diseases.  
A positive relationship between plasma levels of MCP-1 and the insulin resistance 
index (HOMA) was observed in this study. This association has also been shown in mice 
and humans. For example, Kamei et al. (2006) demonstrated that over expression of 
MCP-1 in transgenic mice resulted in a systemic insulin resistance. In a study by 
Weisberg et al. (2006), insulin sensitivity improved in obese mice treated with an 
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antagonist of CCR2, the MCP-1 receptor. In overweight and obese humans who are 
prone to having low insulin sensitivity, the circulating levels of MCP-1 were positively 
related to HOMA scores (Kim et al., 2006). Thus, it is likely that MCP-1 may participate 
in the pathogenesis of insulin resistance by impairing insulin signaling and reducing 
insulin-mediated glucose uptake (Kamei et al., 2006). 
We also found that circulating concentrations of MCP-1 were positively related to 
liver function markers, plasma ALT and AST. The levels of these liver enzymes are 
known to be elevated in obese and insulin-resistant individuals (Colicchio et al, 2005). 
MCP-1 may be associated with elevated levels of ALT and AST through its contribution 
to both insulin resistance and hepatic inflammation. Thus, the disruption of insulin 
signaling in adipocytes due to inflammatory molecules may lead to ectopic fat deposition 
(Raz et al., 2005). This triglyceride accumulation in the liver may then increase the 
susceptibility to hepatic inflammation and apoptosis. Subsequently, these events may lead 
to a release of hepatocyte constituents into the circulation and raising the blood levels of 
liver injury markers.  
The serum levels of MCP-1 are elevated in individuals with steatosis, with the 
highest concentrations in subjects with non-alcoholic steatohepatitis (Haukeland et al., 
2006). The association between MCP- 1 and NAFLD is strengthened further by the 
findings of Kanda et al. (2006) who showed that insulin resistance and hepatic steatosis 
were ameliorated due to the deletion of the MCP-1 gene in mice that were fed a high fat 
diet. 
Although baboons have been used extensively for the study of alcoholic fatty liver 
disease (Navder et al., 1999; Savolainen et al., 1986; Lieber et al., 1985), this is the first 
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time that this primate has been used as a model for obesity-related, hepatic pathology. In 
summary, this paper suggests that elevated plasma levels of MCP-1 and reduced 
adipocyte cell number are inversely related. This endogenous, immunomodulatory 
chemokine might promote adipocyte dedifferentiation (reduced cell number) events that 
may interfere with insulin-mediated glucose uptake and subsequent insulin resistance. 
Ultimately, obesity-related inflammation, in conjunction with insulin resistance, may lead 
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Figure 2.1 The association between the plasma monocyte chemoattractant protein 1 
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Figure 2.2 The association between the plasma monocyte chemoattractant protein 1 
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Figure 2.3 The association between the plasma monocyte chemoattractant protein 1 
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Figure 2.4 The association between the plasma monocyte chemoattractant protein 1 
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Chapter  3  
Identification of a QTL for Adipocyte Volume and of Shared Genetic Effects 




Non-alcoholic fatty liver disease is a hepatic condition that affects a large number 
of overweight and obese individuals. Aspartate aminotransferase (AST) is one of the liver 
enzymes whose concentration is elevated in patients with visceral obesity. The purpose of 
this study was to examine if adiposity related parameters are under genetic influence and 
to evaluate their genetic correlations with AST.  
Fasting plasma of 374 pedigreed baboons from the Southwest National Primate 
Research Center at the Southwest Foundation for Biomedical Research, San Antonio, TX 
were assayed for AST. Adipocyte volume and number were measured using biopsies of 
omental adipose tissue. Genetic analyses were conducted by a maximum likelihood based 
variance decomposition approach implemented in the computer program SOLAR. 
Adipocyte volume and number, body weight and plasma AST were highly heritable. 
Genetic correlations between the measured adiposity - related phenotypes and AST were 
significant. A genome wide scan yielded a strong signal for adipocyte volume on the 
baboon homologue of human chromosome 6 with a maximum LOD score of 3.2 at 73 cM 
near marker D6S1028.  These results suggest that the size of omental adipocytes is under 
significant genetic control and that shared genetic factors influence adiposity associated 





In obesity, white adipose tissue enlarges due to increased adipocyte size 
(hypertrophy) and/or number (hyperplasia) (Hausman et al., 2001). Adipocyte size is a 
function of the balance between lipogenesis and lipolysis (Schling and Loffler, 2002). 
However, fat cell number is controlled by the equilibrium between proliferation (or 
differentiation) and apoptosis (Avramm et al., 2005). It is postulated that failure of 
preadipocytes to differentiate into mature lipid storage cells expands the existing 
adipocytes during periods of surplus energy intake (Heilbronn et al. 2004). The resultant 
hypertrophic cells are known to have dysfunctional lipid and glucose metabolism (Smith 
et al., 2006), leading to insulin resistance (Mc Garry and Dobbins, 1999) and ectopic fat 
accumulation in tissues other than adipose depots (Danforth E, 2000).  
Most obesity related diseases are associated with hypertrophic adipocytes 
(Greenberg and Obin, 2006). The large fat cells are highly susceptible to apoptosis 
because of stress and consequently they attract mononuclear cells (Chen et al., 2005). The 
recruited macrophages secrete cytokines that impair insulin sensitivity of the surrounding 
fat cells within the tissue (Shi et al, 2006). The insulin resistance augments lipolysis, 
resulting in elevated concentrations of unesterified fatty acids in the circulation. 
Consequently, high plasma levels of insulin and free fatty acids may induce hepatic 
steatosis by the up regulation of the synthesis and accumulation of triglycerides in the 
liver (Mendez-Sanchez et al., 2006). 
It is hypothesized that omental adiposity is directly related to non-alcoholic fatty 
liver disease (NAFLD) (Adams and Angulo, 2005) because blood supply from visceral 
adipose tissue drains directly into the liver via the portal vein. Donelley et al. (2005) have 
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shown that 60% of the triglycerides accumulated in the liver are derived from the visceral 
adipocytes. One of the features of NAFLD is elevated levels of liver enzymes. Aspartate 
aminotransferase (AST), a liver enzyme is the key focus of this paper as it is elevated in 
patients with visceral obesity and fatty liver disease (Cancello et al 2006). The variation 
in the circulating levels of this enzyme is under genetic influence in humans (Bathum et 
al., 2001). Also, it is well established that genetic factors contribute to obesity related 
phenotypes. Therefore, the goal of this study is to identify specific chromosomal regions 
that might affect adipocyte size and number and to determine if common genetic factors 
regulate these adiposity traits and AST in baboons.  
Baboons from the colony at the Southwest National Primate Research Center 
were used as the animal model. Approximately 10% of these animals become obese 
spontaneously, in spite of similar diet and environmental conditions (Comuzzie et al., 
2003). This finding implies that a strong genetic component influences the obesity related 
phenotypes in these animals. In terms of evolution, humans and baboons have similar 
DNA and gene sequences (Rogers and Hixson, 1997). For example, the similarity in their 
protein structure makes it possible to use human assay kits for the analysis of baboon 
proteins. Furthermore, both humans and baboons exhibit central obesity, with fat 
deposition occurring in the visceral adipose tissue (Comuzzie et al., 2003) and these 
animals exhibit the whole spectrum of histological changes associated with NAFLD 
(Bose et al, 2006). Moreover, it is more feasible to obtain omental adipose tissue biopsies 
from a large number of pedigreed baboons than it is in humans. Thus, baboons serve as 




3.3 Materials and methods 
 
Animals 
This study included 374 (254 females, 119 males) pedigreed baboons (Papio 
hamadrayas) housed at the Southwest National Primate Research Center located at the 
Southwest Foundation for Biomedical Research (SFBR) in San Antonio, TX, USA. These 
animals are gang-housed and fed a low fat standard monkey chow diet ad libitum (Harlan 
Teklad 15% monkey diet, 8715, Indianapolis, IN).  
Sampling and Phenotypic analyses 
 
Animals were fasted overnight (12 hours) and sedated with ketamine prior to collection 
of blood samples. Body weight was measured on a calibrated electronic scale (GSE, Chicago, 
IL). A total of 10 ml of blood was drawn from the antecubital vein in heparin tubes for analysis 
of AST. Plasma was obtained by centrifugation at 2000 x g for 10 minutes and was stored in 
aliquots at –80
0
 C for future analysis. The Institutional Animal Care and Use Committee of the 
SFBR approved all procedures. Assay of AST was conducted by standard laboratory 
techniques using Alfa Wasserman ACE clinical chemistry instrument (West Cladwell, NJ). 
Omental adipose tissue biopsies were collected as previously described by Cole et al. (2003).  
Adipocyte volume and fat cell number per gram of tissue were analyzed by the method of 
Lewis (1986). All samples whose replicates had >5% variations were reanalyzed.  
Genotyping 
Using human PCR primers, homologous loci from baboon genomic DNA were 
amplified to construct a baboon genetic linkage map (Rogers et al., 2000). Electrophoresis was 
used to obtain baboon genotypes via ABI 373 and ABI 377 automated sequencers using 
fluorescently labeled primers. Genescan and Genotyper software (Applied Biosystems, Foster 
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City, CA) were utilized for genotype scoring. A map with an average marker density of 10 cM 
was created using 331 markers.  
Statistical genetic methods 
The maximum likelihood based variance decomposition method was used to 
perform the quantitative genetic analyses. The phenotypic variance of a quantitative trait 
was decomposed into additive genetic and nongenetic (environmental) components. The 
proportion of variance in a phenotype due to additive genetic effect was defined as 
heritability. (h
2
). The likelihood ratio test compares the likelihood of a model whose h
2 
was estimated to the likelihood of a model whose h
2 
was restricted to zero. Twice the 
difference of the log likelihoods was asymptomatically distributed as ½: ½ mixture of 
chi-sqaure variable, with one degree of freedom and a point mass at zero (Self and Liang, 
1987). 




bivariate genetic analyses. The 
bivariate phenotype is a result of the animal’s phenotypic values, population means, the 
additive genetic estimates and environmental effects. This model was used to calculate 
the genetic and environmental variance-covariance matrices, in addition to genetic and 
environmental correlations. Both univariate and bivariate genetic analyses were 
conducted using the Sequential Oligogenic Linkage Analysis Routinues (SOLAR) 
computer program (Almasy and Blangero, 1998). Age, sex, age squared and their 
interactions were included as covariates for the analyses. Software program PEDSYS 





The number of relative pairs studied in the sample analyzed is shown in Table 3.1. 
The descriptive statistics of the baboons according to sex are displayed in Table 3.2. 
There were twice as many females as males, and the female baboons were significantly 
older and had lower body weights. However, males had a higher concentration of plasma 
AST and smaller adipocyte volume. Adipocyte number did not vary significantly.  
The heritabilities for body weight, plasma AST, and adipocyte volume and 
number are given in Table 3.3. All of these heritabilities were significant with body 
weight having the highest heritability of all the traits studied. Table 3.4 shows the genetic 
correlations between plasma concentration of AST and adiposity markers. Circulating 
concentrations of AST had a positive association with body weight and adipocyte volume 
and a negative relationship with adipocyte number.  
The genome wide scan for adipocyte volume is shown in Figure 3.1. The 
strongest signal obtained was detected on the baboon homologue of human chromosome 
6, with a maximum LOD score of 3.2 at 73 cM near marker D6S1028 (Figure 3.2).  
3.5 Discussion 
 
This is the first study to identify a significant QTL for adipocyte volume and also 
report significant genetic correlations between AST and omental adipocyte number and 
volume and body weight. Aspartate aminotransferase (AST) also called glutamate 
oxaloacetate transaminase, is a pyridoxal phosphate-dependent enzyme that participates 
in amino acid metabolism as well as the urea and tricarboxylic acid cycles in the liver 
(Panteghini, 1990). The levels of this enzyme are elevated in obese subjects (Marchesini 
et al.,2005), presumably due to the NAFLD, which is highly prevalent in these 
individuals (Gholam et al., 2007). In these patients, visceral adiposity, coupled with the 
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presence of insulin resistance, may link obesity to fatty liver disease (Angelico et al., 
2005). 
Adipocytes comprise about 0.5 to 1 % of the total body cells. The weight of the 
adipocytes accounts for approximately 2-3 % of the body weight in a healthy person, as 
opposed to 30-40% in the obese (Prins and O’Rahilly, 1997). In obesity, hyperplasia and 
hypertrophy cause expansion of the adipose tissue mass. It is believed that during weight 
gain adipocytes increase in size to accommodate the newly synthesized triglycerides 
(Spiegelman and Flier, 1996). However, once a threshold size is achieved, the fat stores 
then expand due to differentiation of pre-adipocytes (Bjorntorp, 1996). 
It is hypothesized that fat cells have a limited capacity to expand (Kawada et al., 
2001). Once the enlarged cells reach a critical mean volume they are liable to rupture due 
to stress (Monteiro et al., 2006), after which fat depots expand due to hyperplasia. 
(Coppack, 2005). However, if the preadipocytes fail to proliferate and differentiate into 
mature fat cells it is plausible that this inability might lead to obesity related diseases 
(Bakker et al., 2006). 
 
 
The dead adipocytes activate inflammatory signaling pathways. These pathways 
could compromise the insulin sensitivity of the remaining fat cells (Cinti et al., 2005).
 
In 
addition, dead cells attract macrophages into the adipose tissue to clear cellular debris 
(Weisberg et al., 2003). These immune cells release cytokines into the milieu, which 
further exacerbates insulin resistance within the adipose tissue (Xu et al., 2003). The 
impairment of insulin signaling, in turn, stimulates lipolysis and increases the circulating 
concentrations of unesterified fatty acids (Permana et al., 2006). These free fatty acids 
that are released, particularly from the visceral fat depots, are transported to the nearby 
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organs such as the liver and may cause organ damage by initiating hepatic triglyceride 
accumulation (Eguchi et al., 2006).  
In this study we found a significant genetic relationship between plasma levels of 
AST, body weight and adipocyte volume. These results imply that the same genetic 
factors may influence these adiposity-related traits and levels of AST. The negative 
association between circulating AST and adipocyte number suggest that a reduced 
number of mature adipocytes might lead to fat accumulation that damages the liver, 
thereby raising the blood levels of AST. 
The identification of a QTL for omental adipocyte volume is the other significant 
finding of this study. Larger cells have been implicated in the development of type II 
diabetes (Weyer et al., 2000) and high plasma levels of non-esterified fatty acids 
(Paolisso et al., 1995). It has been shown that bigger fat cells have higher mRNA 
concentrations of enzymes involved in lipid synthesis and hydrolysis than do those of a 
smaller size (Farnier et al, 2002). Moreover, the hypertrophic adipocytes apear to be 
metabolically dysregulated.  
Adipocyte size also affects the secretion of cytokines. Hypertrophy induces the 
release of pro-inflammatory adipokines which might be responsible for the chronic state 
of inflammation in obesity (Skurk et al., 2006). Fat cells with a larger volume produce 
significantly more chemoattractants which attract monocytes into the adipose tissue. The 
cytokines released by these immune cells negatively affect the differentiation of 
preadipocytes (Stephen et al., 1993) and promote apoptosis of the existing cells (Lin et 
al., 2004). Therefore, in addition to total fat mass, both the size and number of cells that 
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constitute the adipose tissue play a major role in the pathology of obesity related co-
morbidites.  
Two potential positional candidate genes present within one LOD support interval 
of the signal for adipocyte volume on Chromosome 6 are fatty acid binding protein 
(FABP7) (OMIM 602965) (Shimizu et al., 1997) and forkhead transcription factor 
(FOXO3A) (OMIM 602681) (Anderson et al., 1998). Fatty acid-binding proteins are 
small proteins that increase the transfer of fatty acids into the cell and enhance the 
catalytic action of enzymes involved in fatty acid metabolism. It is believed that FABP 
helps to maintain the systemic energy homeostasis by providing a critical link between 
lipid metabolism and cellular functions in adipose tissue and other organs (Maeda et al., 
2005). The other candidate gene, forkhead transcription factor is stimulated due to stress 
and induces the expression of genes related to cell death. Its expression has been 
upregulated in rats fed a high fat diet suggesting that apoptotic pathways might be 
activated in obesity (Relling et al., 2006).  
In conclusion, this study establishes that the volume and number of adipocytes are 
heritable. The bivariate genetic analyses demonstrate that AST levels, fat cell volume and 
number and body weight are regulated by common genetic factors. Future work should 
identify polymorphisms in the chromosomal region of the QTL for adipocyte cell number 
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Table 3.3  Heritabilities of body weight, aspartate aminotransferase and adipocyte 
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Table 3.4  Genetic (rhoG) correlations between plasma concentration of aspartate 



















































Figure 3.1  Genome-wide scan of adipocyte volume. 







































Chapter 4  
QTLs Regulating Plasma Levels of GGT and ALB and their Genetic Correlations 
with Cardiovascular Risk Factors 
4.1 Abstract 
 
Gamma glutamyl transferase (GGT) and albumin (ALB) are two markers of liver 
function. These two proteins have been associated with non-alcoholic fatty liver disease 
and cardiovascular disease. The objective of this study was to explore the genetic factors 
that influence variation in the plasma levels of GGT and ALB and to evaluate their 
genetic correlations with cardiovascular risk factors. Baboons from the Southwest 
National Primate Research Center at the Southwest Foundation for Biomedical Research, 
San Antonio, TX were used as an animal model. The baboons were fed a standard 
monkey chow diet ad libitum. Fasting plasma concentrations of GGT, ALB, triglycerides, 
total cholesterol and LDL cholesterol were measured in 350 pedigreed adult baboons by 
standard assay procedures. A maximum likelihood based variance decomposition 
approach implemented in the computer program SOLAR was used to conduct genetic 
analyses. The heritabilities of GGT (h
2
=0.55; p< 0.0001) and ALB (h
2
=0.42; p< 0.01) 
were significant. No statistically significant associations were found between GGT and 
the cardiovascular related phenotypes. Genetic correlations between ALB and 
cardiovascular risk factors were significant. A QTL (LOD = 2.8) for GGT plasma levels 
was identified on the baboon homologue of human chromosome 22 between markers 
D22S304 and D22S280. A QTL (LOD =2.3) near marker D10S1432 was detected on the 
baboon homologue of human chromosome 10 for ALB. These results imply that 
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variations in the plasma levels of GGT and ALB are under significant genetic regulation 




The leading cause of an abnormal liver function test in overweight and obese 
individuals is non-alcoholic fatty liver disease (NAFLD) (Ekstedt et al, 2006). This 
hepatic pathology encompasses simple steatosis, steatohepatitis, fibrosis and cirrhosis 
(Liou  and Kowdley , 2006). In the pathogenesis of this disease, a “two-hit model” 
implicates obesity related factors such as visceral obesity, insulin resistance and 
dyslipidemia (Day, 2002). According to this model, the first hit takes place when 
monocytes infiltrate the omental adipose tissue to scavenge adipocytes that have 
undergone necrosis due to stress within the tissue (Cinti et al., 2005). The immune cells 
secrete cytokines in the milieu which disrupts the insulin signaling pathways of the 
surrounding adipocytes (Lumeng et al., 2006). Absence of the lipogenic control of insulin 
enhances lipolysis within the adipocytes. Consequently, elevated concentrations of free 
fatty acids and insulin are directed to the liver from the adipose tissue (Utzschneider and 
Kahn, 2006). The unesterified fatty acids accumulate in the liver as triglycerides because 
insulin upregulates the hepatic synthesis of triglycerides through activation of sterol 
regulatory binding protein (SREBP-1C) (Kotani et al., 2004). This ultimately leads to 
hepatic steatosis (Gaemers and Groen , 2006).  
In the second hit steatosis leads to the advanced stages of NAFLD. Fat stored in 
the liver undergoes oxidation in the mitochondria which generates reactive oxygen 
species (Begriche et al., 2006). These free radicals result in lipid peroxidation, cytokine 
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induction and apoptosis, which lead to inflammation, fibrosis and cell death (Videla et 
al., 2006).  
Epidemiological studies have shown a strong positive relationship between 
markers of NAFLD such as liver enzymes and prevalence of cardiovascular disease 
(CVD) (Schindhelm et al., 2006; Targher et al, 2006). The focus of this paper is on two 
indicators of liver function, gamma-glutamyl transferase (GGT) and albumin (ALB), both 
of which have also been implicated in the pathogenesis of atherosclerosis. It is known 
that the variation in the plasma level of these liver related proteins is genetically 
influenced. To explore these genetic factors and also to evaluate the relationship of these 
liver markers with cardiovascular risk phenotypes we have chosen the baboon as an 
animal model.  
The pedigreed baboons from the colony maintained by the Southwest National 
Primate Research Center are an excellent model for this study since the availability of 
large extended pedigrees gives statistical power. Although all the baboons share similar 
diet and housing conditions, 10% become obese spontaneously and 4% become 
hyperglycemic (Comuzzie et al., 2001). Gene and protein sequence identity is conserved 
between baboons and humans and both are physiologically and developmentally similar. 
For example, during weight gain fat is deposited primarily in the abdominal area of 
baboons. It
 
has been known that visceral adiposity is strongly linked to several metabolic 
diseases such as cardiovascular ailments, type 2 diabetes and fatty liver (Licata et al., 
2006). Obese and insulin resistant baboons from this colony have been diagnosed with 
hepatic steatosis, steatohepatitis and fibrosis (Bose et al., 2006). In addition, baboons 
have been used for genetic studies related to atherosclerosis (Mahaney et al., 1999), 
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insulin-resistance (Cai et al., 2004), obesity (Tejero et al., 2005) and liver gene 
expression (Cox et al., 2006).  
The purpose of this study is to identify chromosomal regions that affect the 
variation in the plasma levels of GGT and albumin and to determine the genetic 
correlations between these liver related proteins and cardiovascular related parameters.  
4.3 Materials and methods 
 
Animals 
The study population consisted of 350 ( 254 females, 96 males) pedigreed baboons 
(Papio hamadrayas) from the colony maintained at the Southwest National Primate Research 
Center located at the Southwest Foundation for Biomedical Research (SFBR) in San Antonio, 
TX, USA. The baboons are gang housed and fed a standard monkey chow diet ad libitum 
(Harlan Teklad 15% monkey diet, 8715, Indianapolis, IN).  
Sampling and Analyses 
Blood samples were drawn after an overnight fast (12 hours) from animals sedated with 
ketamine. Heparin tubes were used to collect samples for analysis of GGT, albumin, 
triglycerides, total cholesterol and LDL cholesterol. The samples were subjected to 
centrifugation at 2000 x g for 10 minutes and the resultant plasma was stored in aliquots at –
80C for future analysis. The animals were weighed on a calibrated electronic scale (GSE, 
Chicago, IL). The Institutional Animal Care and Use Committee of the SFBR approved all 
procedures. 
Triglycerides, total cholesterol, LDL cholesterol, GGT and albumin were analyzed by 
standard laboratory techniques using the Alfa Wasserman ACE clinical chemistry instrument 





A baboon genetic linkage map was constructed by amplifying homologous loci from 
baboon genomic DNA using human PCR primers (Rogers et al., 2000). Electrophoresis of PCR 
products occurred on ABI 373 and ABI 377 automated sequencers using fluorescently-labeled 
primers, and genotypes were scored using Genescan and Genotyper software (Applied 
Biosystems, Foster City, CA). A map with an average marker density of 10 cM was generated 
using 331 markers.  
Statistical genetic methods 
The quantitative genetic linkage analyses for the target phenotypes were conducted 
using the variance decomposition methods implemented in the computer package SOLAR 
(Almasy and Blangero, 1998). The variance component approach incorporates all of the genetic 
linkage information in the extended pedigrees, assuming all possible biological relationships 
simultaneously. Power-diminishing, simplifying assumptions that are integrated in most 
"penetrance model free" methods are relaxed in the extensions of this method. The variance 
component method is more efficient since it requires the estimation of fewer parameters than 
the fully parametric penetrance-based linkage methods. 
The variance component linkage method is based on classical quantitative genetic 
principles, in which the phenotype is assumed to be influenced by both genetic and 
environmental factors. Unlike the classical models, the genetic factors can include specific loci 
at defined chromosomal locations.  Evidence for genes is obtained from the observed 
covariances (or correlations) among different classes of relatives. The a priori structure for 
these correlations among individuals in a family is provided by a matrix that contains the 
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coefficients of relationship for all pairs of individuals, which also are the prior probabilities that 
two individuals will share a particular allele identical-by-descent. 
In the variance component approach, the observed covariances among individuals are 
compared to expected covariances obtained under the linkage model including both the locus-
specific and genomic factors, each of which is quantified by a variance component. If the 
variance component for a specific chromosomal location is significantly greater than zero, there 
is evidence for a locus influencing the phenotype at that location. Evidence for such a locus 
requires that the statistical "fit" of the observed phenotypic covariances and the expected 
covariances (given the linkage model under consideration) be significantly better when the 
locus-specific component is allowed than when it is not.  
Parameter estimation and hypothesis testing are performed using a likelihood 
framework, assuming multivariate normality as a working model within pedigrees. For each 
phenotype, we will test the null hypothesis that the additive genetic variance due to a specific 
QTL equals zero (no linkage) by comparing the likelihood of this restricted model with that of 
a model in which the variance due to this QTL is estimated.  
The difference between the two log10 likelihoods yields a LOD score, which measures 
the support for the hypothesis of linkage over that of "no linkage" at a given chromosomal 
location. A LOD score of 3.0, for example, indicates that the statistical support for the linkage 
hypothesis is 10
3
 times more than for the null hypothesis. P-values for this test are obtained 
from twice the difference in loge likelihoods of these two models, which yields a test statistic 
that is asymptotically distributed as a (1/2):(1/2) mixture of a chi square variable and a point 






Information describing the number of relative pairs represented in the sample for these 
analyses is provided in Table 4.1. Descriptive statistics of the phenotypes according to sex are 
given in Table 4.2. Male baboons were younger and had higher body weights than females due 
to the sexual dimorphism in these animals (Tejero et al., 2004). Female baboons had higher 
levels of plasma total cholesterol, LDL cholesterol and triglycerides. The plasma concentration 
of GGT was elevated in male baboons, but no difference between the sexes was observed for 
albumin. 
Table 4.3 shows the heritabilities of liver function markers and cardiovascular risk 
factors analyzed as part of this study. All were significantly heritable with total cholesterol 
exhibiting the greatest hertitability. Table 4.4 gives the genetic correlations between plasma 
GGT, albumin and plasma lipids. No statistically significant association was found between 
GGT and the cardiovascular related phenotypes. However, negative relationship between 
plasma albumin and lipids was significant. 
The results of a genome wide scan by each chromosome for plasma GGT are displayed 
in Figure 4.1. A suggestive signal for  GGT was observed on the baboon homologue of human 
chromosome 3 (LOD score 1.95) at marker D3S1300. The strongest QTL for GGT was 
detected between markers D22S304 and D22S280 on the baboon homologue of human 
chromosome 22, at approximately 30 cM with a LOD score of 2.8. This linkage signal is shown 
in greater detail in Figure 4.2. The maximum LOD score detected in a genome wide linkage 
scan for albumin was detected on the baboon homologue of human chromosome 10 (Figure 
4.3), with a LOD score of 2.3 at 66 cM near marker D10S1432 (Figure 4.4). 
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4.5 Discussion  
 
This study has demonstrated that the variation in the plasma levels of GGT and albumin 
are influenced by genetic factors. The heritability estimates of these liver function markers in 
baboons are similar to that found in humans. Heritability estimates of GGT were 52% in 
Australian men and women (Whitefield et al. 2002) and 62% in Danish twins (Bathum et al., 
2001), as compared to 55% found in this study. For albumin the additive genetic effect in adult 
men and women was 36%, which is lower than the value calculated for baboons in this paper 
(Pankow et al., 2001). This is the first study to publish the QTLs for GGT and albumin in 
baboons and there is no published information on QTLs for these proteins yet published in 
humans.  
Even though phenotypic correlations between albumin and cardiovascular risk factors 
have been reported (Schalk et al., 2006; Beddhu et al., 2002; Krijgsman et al., 2002), the 
evidence of shared genetic effects (i.e. pleiotrophy) between them has been detected for the 
first time in this paper. The associations found here imply that same set of genes regulate their 
circulating concentrations. 
The most common cause of abnormal liver function is NAFLD, a disease that affects 
approximately 15-25% of the world’s population. The prevalence is higher in the obese and 
type 2 diabetics (Adams and Angulo, 2005). Patients with NAFLD might be at a higher risk for 
cardiovascular disease than those without this hepatic condition (Targher G, 2007). The 
findings of this paper suggest that common genetic factors might be responsible for both of the 
pathologies.  
Gamma glutamyl transferase and albumin are markers of both liver function and 
oxidative stress. Plasma GGT is a well-established and sensitive marker of hepatic dysfunction. 
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This enzyme which is present on the cell membrane catalyzes the hydrolysis of extracellular 
glutathione, a primary cellular antioxidant (Lee et al., 2004). During the metabolism of 
glutathione by GGT, ferric iron is reduced to the ferrous form. This reaction generates reactive 
oxygen species that promote the oxidation of LDL cholesterol (Dominici et al., 2005). It is well 
established that oxidized cholesterol participates in deposition of atherosclerotic plaques. 
(Meisinger et al., 2006). The circulating concentration of GGT is elevated in CVD and NAFLD 
patients, (Ruttmann et al., 2006; Marchesini et al., 2005), implying that it might a link between 
the two diseases. Yet, in this study we did not detect any significant genetic relationship 
between GGT and cardiovascular risk factors. 
In contrast, a significant negative genetic correlation between albumin and 
cardiovascular risk factors was observed in this study. Traditionally, plasma albumin has been 
considered to be a good bio-marker of protein malnutrition but now this protein is associated 
with heart disease (Schalk et al., 2006). The sulphydryl groups (thiols) in albumin scavenge 
reactive oxygen species and dampen oxidative stress by binding free copper (Cu
2+
), an ion 
necessary for the production of free radicals (Don and Kaysen, 2004). In addition, albumin has 
the ability to bind to free fatty acids, thereby; reducing synthesis of triglycerides and LDL 
cholesterol. Since the liver manufactures albumin, damage to this organ reduces the blood 
levels of this protein (Tietge et al., 2004). Lower levels of albumin raises the concentration of 
unbound free fatty acids that consequently increases the amount of lipid parameters in the 
blood (Ha et al., 2006).  
Insulin resistance and oxidative stress are hypothesized to be the link between fatty liver 
abnormalities and heart disease (Palomo et al., 2006). Another plausible mechanism associating 
these two disorders could be abnormal lipoprotein metabolism in individuals with steatotic 
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liver, i.e. elevated plasma concentrations of triglycerides and low density lipoprotein 
cholesterol (LDL) (Targher and Arcora, 2006). The high prevalence of cardiovascular disease 
in NAFLD patients could be due to insulin resistance that results in dyslipidemia (Oretga et al., 
2006).
 
It is believed that the increased assembly of very low density lipoproteins (VLDL) in the 
liver causes hypertriglyceridemia and elevated levels of low density lipoprotein (LDL) (Julius, 
2006). Although insulin is known to degrade apolipoprotein B, a constituent of VLDL, this 
effect is removed in a state of hepatic insulin resistance. Consequently, the triglycerides stored 
in the steatotic liver are packaged into the VLDL and secreted into the circulation (Taghibiglou 
et al., 2000). Additionally, insulin resistance is characterized by a reduced efficiency of 
lipoprotein lipase to clear these particles from the blood, resulting in high levels of LDL since 
VLDL is metabolized into LDL (Ginsberg, 2006). Finally, the expression of LDL receptors on 
the liver is downregulated in an insulin resistant liver (Mamo et al., 2001). Ultimately, all of the 
above increases the plasma levels of atherogenic factors that are known to increase the risk of 
atherosclerosis.  
For GGT, potential positional candidate genes (based upon the homologous region in 
humans) that are present within the one LOD-support interval of the maximum linkage signal 
on chromosome 22 include selenoprotein Z (TRXR2) (Sun et al., 1999),  mitogen- activated 
protein kinase 1 (MAPK1) (Li et al., 1994),  macrophage migration inhibitory factor (MIF) 
(Bozza et al., 1995), gamma glutamyltransferase 1 (GGT1) and gamma glutamyltransferase 2 
(GGT2) (Figlewicz et al., 1993). The most promising positional candidate genes within this 
QTL are the two structural genes that produce the two isoforms (GGT1 and GGT2) of GGT. 
The genes of interest within the one LOD support interval of the albumin QTL on chromosome 
10 are insulin degrading enzyme (IDE) (Espinosa et al.,1991), stearoyl –CoA desaturase (SCD) 
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(Zhang et al., 1999), cytochorme P450 subfamily IIC, and polypeptide 9 (CYP2C9) (Gray et al., 
1995). All of these genes are related to oxidative stress.  
In conclusion, this study indicates that a significant genetic component affects 
circulating levels of GGT and albumin. A common set of genes appear to regulate plasma 
levels of albumin and cardiovascular related risk factors. These findings support the complex 
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Table 4.4  Genetic (rhoG) correlations between plasma concentration of gamma 











Phenotype ρ  Genetic p value ρ  Genetic p value 
Total cholesterol 0.18 0.39 -0.60 0.01 
LDL cholesterol 0.26 0.35 -0.67 0.01 










Figure 4.1  String plot of the genome wide scan of plasma concentrations of gamma 
glutamyl transferase. The y–axis indicates the chromosomal location in cM and the x-axis 















































Figure 4.3  String plot of the genome wide scan of plasma concentrations of albumin. 













































Chapter 5  
Relationship of liver function markers to non-alcoholic fatty liver disease in baboons 
 
5.1  Abstract 
 
Non-alcoholic fatty liver disease (NAFLD) is characterized by hepatic 
triglyceride accumulation in the absence of excessive alcohol consumption. This disease 
often coexists with conditions like obesity and insulin resistance. The primary aim of this 
study was to determine the presence of NAFLD in baboons. The secondary aim was to 
investigate the association between liver function parameters and various categories of 
NAFLD. 
The study population consisted of 39 baboons housed in a colony maintained at the 
Southwest Foundation for Biomedical Research (SFBR) in San Antonio, TX, USA. They 
were fed ad libitum on a standard monkey chow diet (Harlan Teklad 15% monkey diet, 
8715, Indianapolis, IN). The animals selected for this project did not have a history of 
hepatic infection or abnormalities. Fasting plasma levels of alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), γ glutamyl transferase (GGT) and albumin 
(ALB), glucose and insulin were assayed by standard laboratory techniques. Hepatic 
triglyceride was extracted and measured enzymatically. Insulin resistance was calculated 
by the homeostatic model assessment (HOMA) method. Liver samples were obtained 
from baboons during necropsy and were stored at -80
0
C. The liver slides were prepared 
by standard procedure using thawed liver specimens. The liver specimens were analyzed 
by two pathologists for histological changes. The findings of this study were inconclusive 
since the diagnoses of the two pathologists were different from each other. This might be 
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due to the different grading scales used by each of the histopathologists. Additionally the 
grading is based somewhat on the subjectivity of each of the pathologists.  
5.2    Introduction 
 
 Non-alcoholic fatty liver disease (NAFLD) is the primary reason for liver related 
deaths in the overweight and obese people (Falck-Ytter et al., 2001). This disease initiates 
with accumulation of triglycerides in the hepatocytes, and eventually progresses to 
steatohepatitis, fibrosis and cirrhosis (Matteoni et al., 1999). The prevalence of hepatic 
steatosis and non-alcoholic steatohepatitis (NASH) in the general population is 20-30 % 
and 2-3%, respectively (Yu and Keeffe, 2002).The incidence of hepatic steatosis is far 
greater (50-70%) in obese individuals (Wanless and Lentz, 1990). 
 Important predictors of NAFLD are obesity (Angulo et al., 1999), insulin 
resistance (Dixon et al., 2001) and dyslipidemia (Chen et al., 2006). It is believed that 
during these metabolic disturbances, regulation of hormone sensitive lipase by insulin is 
impaired which increases triglyceride hydrolysis and free fatty acids release from 
adipocytes (Jaworski et al., 2007). At the same time, insulin resistance also elevates the 
circulating levels of glucose and insulin (Stump et al., 2006). Higher uptake of free fatty 
acids by the liver and up regulation of hepatic lipogenic genes by insulin elevates the 
triglyceride pool in the liver. Insulin also promotes the reesterification of fatty acids 
rather than oxidation (Diraison et al., 2003), in addition to impeding the export of 
triglycerides (Gibbons et al., 2002) from the liver. Moreover, import of unesterified fatty 
acids to the hepatocytes may surpass the mitochondrial oxidation capacity and, 
ultimately, favor triglyceride accumulation (Vendemiale et al., 2001). This fat deposition 
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in the liver exposes the liver cells to further injury from free radical species which results 
in non-alcoholic fatty liver disease. 
In lipid-laden liver free fatty acids induce the expression of genes involved in 
fatty acid oxidation in the mitochondria, as well as peroxisomes or microsomes, via 
stimulation of the peroxisomal proliferator-activated receptor-α (Jansen P, 2004). 
However, reactive oxygen radicals are generated during the oxidation of unesterified free 
fatty acids (Natarajan et al., 2006). Consequently, oxidative stress results in neutrophil 
infiltration, leading to steatohepatitis or inflammation.  
 Liver biopsy is the only method that can truly distinguish between the different 
stages of the NAFLD (Hubscher S, 2004). However, due to cost and risk associated with 
biopsy it is not feasible to perform this procedure for all patients suspected to have 
NAFLD. Non-invasive methods such as ultrasound (Joy et al., 2003), computer 
tomography (Limanond et al., 2004), and magnetic resonance imaging (Saadeh et al., 
2002) are ideal for measuring the extent of liver damage due to steatosis. Liver injury 
markers (Schindhelm et al., 2006) are the cheapest and most convenient method used 
widely to diagnose liver dysfunction; but these are not the most reliable indicator of the 
status of fatty liver disease. None of these techniques surpass the sensitivity and 
specificity as great as of liver biopsy (Sanyal A, 2002).  
Some of the baboons maintained in the colony at the Southwest National Primate 
Research Center are known to develop obesity (10%) and insulin resistance (4%), in spite 
of similar diet and environmental conditions. Therefore, these animals are an excellent 
model to study obesity-related diseases (Tejero et al., 2004). The goal of this project is to 
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explore the occurrence of non-alcoholic fatty liver disease and to determine its 
relationship with markers of liver injury in baboons. 
5.3 Materials and methods 
 
Animals 
The study population consisted of 39 (18 males, 21 females) baboons (Papio 
hamadrayas anubis). These animals were gang-housed in a colony maintained at the 
Southwest Foundation for Biomedical Research (SFBR) in San Antonio, TX, USA. They 
were fed ad libitum on a low fat standard monkey chow diet (Harlan Teklad 15% monkey 
diet, 8715, Indianapolis, IN). The animals selected for this project did not have a history 
of hepatic infection or abnormalities. 
Sampling and assays 
All procedures performed were approved by the Institutional Animal Care and 
Use Committee of the SFBR. Blood samples were collected following an overnight fast 
(12 hours) from the antecubital vein of animals sedated with ketamine prior to necropsy. 
The samples were centrifuged at 2000 x g for 10 minutes and the plasma was stored in 
aliquots at –80
0
C for future analyses. The weights of the animals were measured on a 
calibrated electronic scale (GSE, Chicago, IL). Liver proteins were assayed by standard 
laboratory techniques using an Alfa Wasserman ACE clinical chemistry instrument (West 
Cladwell, NJ). Hepatic triglycerides were extracted by the method described by Folch et 
al. (1957). Triglyceride content of the tissues was measured enzymatically, using a 
commercial reagent (Stanbio Laboratory, Boerne TX), in a spectrophotometer at 550 nm. 
Glucose was analyzed by the glucose oxidase method on an Analox
 
spectrophotometer 
(Tejero et al., 2004). Insulin was measured by chemiluminescence in a Luminex 100 with 
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endocrine multiplex immunoassay (Linco Research, Inc). Insulin resistance was 
calculated by the homeostatic model assessment (HOMA) method (Matthews et al., 
1985). Samples whose replicates had >5% variations were reanalyzed.  
Histology 
Liver samples were obtained from baboons during necropsy. These liver 
specimens were immediately frozen by dipping in liquid nitrogen. To prepare liver slides 
the tissues were thawed and fixed in formalin, embedded in paraffin to prepare 5 µm 
sections via microtome (Olympus America, Melville, NY), and then stained with 
hematoxilin and eosin (Maislos et al., 2005). The liver specimens were graded by two 
pathologists. The first pathologist (NU) used the Brunt et al. (1999) grading protocol and 
the second pathologist (ED) used the grading scheme proposed by Kleiner et al (2005). 
To compare the results of the two pathologists the animals were grouped into two 
categories. Category 1 contained baboons with either absent or mild steatosis. Baboons 
with steatosis, coupled with lobular inflammation and ballooning, were included in 
category 2.  
Statistical methods 
Descriptive statistics and other statistical analysis were performed using SPSS (SPSS 
Inc., Chicago, IL; V 10.0). Results are expressed as mean (95% confidence interval). 
Student’s tests were performed to determine the difference in the continuous variables 
between the two categories. Pearson chi-square test was performed to compare the results 




5.4      Results 
 
The two categories created in this study to compare the diagnosis of the two 
pathologists are described in Table 5.1. Table 5.2 shows the number of cases diagnosed 
as category 1 and 2 NAFLD by the two pathologists. The findings of each of the 
pathologists are elaborated in Table 5.3. There were no significant differences between 
the diagnoses of the two pathologists for steatosis, ballooning or portal inflammation. 
However, the results for lobular inflammation varied substantially between the two 
pathologists. Descriptive statistics of baboons with NAFLD, based on the diagnosis of the 
first pathologist, are shown in Table 5.4. The ages of the animals in the two groups did 
not differ significantly. The mean weights of the animals in category 2 NAFLD were 
higher, but not significantly, than that of the baboons in category 1. According to the 
grouping for NAFLD by the first pathologist, plasma levels of alanine aminotransferase, 
aspartate aminotransferase, alkaline phosphatase, gamma glutamyl transferase, hepatic 
triglyceride content and insulin sensitivity measured by the homeostasis model 
assessment method (HOMA) did not differ statistically between the two groups. 
However, serum albumin was significantly lower for the baboons with category 2 
NAFLD.  
Descriptive statistics of baboons with NAFLD based on the diagnosis of the 
second pathologist are shown in Table 5.5. In this distribution animals diagnosed with 
NAFLD were older than the baboons with absent or mild steatosis. Weights, and plasma 
levels of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, 
gamma glutamyl transferase, albumin, hepatic triglyceride and insulin sensitivity did not 
differ statistically between the two groups.  
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Figure 5.1 show a healthy baboon liver. Figure 5.2 illustrates the presence of mild 
steatosis in baboon liver (Category 1). Figure 5.3 shows advanced stage of the disease, 
i.e., steatosis coupled with inflammation and ballooning (Category 2). 
5.5       Discussion  
 
This is the first study to investigate the presence of non-alcoholic fatty liver 
disease in baboons and to explore its relationship with liver proteins. Other animal 
models used for the study of fatty liver disease are usually subjected to dietary 
intervention or genetic manipulations (Zou et al., 2006; Ito et al.; 2006; Kainuma et al., 
2006; Shiri-Sverdlov et al., 2005). The uniqueness of this project was the use of captive 
baboons, with a potential to develop spontaneous obesity and insulin resistance that could 
demonstrate the presence of obesity-related hepatic pathology.  
The occurrence of NAFLD was not affected by the sex of the animals. Based on 
earlier human studies it was believed that this condition affected women more than men 
(Powell et al., 1990; Diehl et al., 1988; Lee RG, 1989). Current evidence suggests that 
NAFLD is observed equally in both the sexes (Bacon et al., 1994; Teli et al., 1995). The 
presence of NAFLD has been reported in all age groups. However it is more common in 
older patients, especially those 50 years and older (Patton et al., 2006; Nomura et al., 
1988; Adam et al., 2005). In the present study, based on the findings of the first 
pathologist, no significant difference was found between the ages of the animals in the 
two diagnostic groups. However, based on the findings of the second pathologist, the 
baboons with category 2 NAFLD were significantly older than the baboons with category 
1 NAFLD. This disparity in the results might be due to sample size in each of the groups 
based on the diagnosis of the pathologists.  
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It is well known that the prevalence of fatty liver disease increases with body 
weight (Angulo et al., 1999; Bellentani et al., 2000). It has been documented that 
compared to 10-15% of the lean subjects the occurrence of this hepatic condition is 
observed in about 70-80% of the obese individuals (Sanyal A., 2002). However, in this 
study only the baboons diagnosed as category 2 NAFLD by the first pathologist were 
found to have higher body weight than their counterparts assigned to category 1 NAFLD. 
Based on the results of the second pathologist, significant differences between the 
weights of the animals in each group were not seen. This might be due to various reasons 
such as starvation leading to rapid weight loss (Whitehead, 1980) or other unidentified 
physiological or genetic factors which might present NAFLD like histological changes 
without significant weight gain. 
Interestingly, plasma levels of AST, ALT and GGT in the lean baboons were 
above the cut-off point value (30 IU/L) used for humans (Prati et al., 2002). Although no 
substantial differences in the concentrations of liver functions markers were observed 
between lean and obese, the levels of ALB were significantly lower in obese baboons, as 
compared to lean. Moreover, as seen in humans, the levels of ALT were higher than that 
of AST (Clark J, 2006) in baboons. A notable observation of this research is that the 
circulating amounts of the liver proteins did not vary with the severity of the histological 
lesions. Liver damage biomarkers are known to not correlate with the progression of the 
NAFLD. This is why a liver biopsy is necessary to make an accurate diagnosis of the 
stage of the fatty liver disease (Mofrad et al., 2003). Nonetheless, due to the cost and risk 
involved with biopsies, biochemical indicators are still the preferred medium to gauge the 
prevalence of NAFLD in the population (Ruhl and Everhart, 2003; Clark et al.2003). 
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Insulin resistance has been implicated in the pathogenesis of NASH (Angulo , 
2002). In this sample of baboons, we did not find a substantial increase in HOMA, a 
parameter for insulin resistance, between the healthy baboons and those diagnosed with 
NAFLD. This might be due to the dissimilar results between the two pathologists. 
However, the circulating levels of insulin and insulin resistance index (HOMA) values 
are known to be high in the obese baboons. In this study all the baboons had high HOMA 
values ≥ 3 (Tejero et al., 2004). 
Histological diagnosis of NAFLD was the key feature of this study. Although 
different grading systems were used by the pathologists, some of the histological scores 
were combined for the purpose of comparison and discussion. In this study the presence 
of mild steatosis is assumed to be benign and not a diseased state (Matteoni et al. 1999). 
Thus, the two categories are category 1 which includes baboons with absent or mild 
steatosis. Whereas, baboons in category 2 are diagnosed as NAFLD due to the presence 
of steatosis that is coupled with inflammation and ballooning. Steatosis was commonly 
found in the liver slides of baboons. In this type of steatosis a single large droplet of fat 
occupied the whole cytoplasm displacing the nucleus (Brunt and Tiniakos, 2002). This 
intra-cytoplasmic fat accumulation might occur due to dysregulated import, manufacture 
and export of lipids to the liver (Angulo, 2002). According to the grading system used by 
the first pathologist, steatosis was graded on a scale of 0-3. The scores were given to each 
slides based on the extent of cells that were steatotic, i.e., 0 = none, 1= up to 33%, 2 = 33-
66% and 3 = > 66% (Brunt et al., 1999). However, the second pathologist graded for 
steatosis using a different scale. The presence of less than 5% of steatotic cells was given 
a score of 0, 5-33% = 1, > 33-66% = 2, and > 66% = 3 (Kleiner et al., 2005).  This 
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scoring was no doubt influenced by the subjective nature of these grading scales, 
resulting in wide variation in the diagnoses of the two pathologists. At this point it is still 
unknown which pathologist was accurate in their interpretation of the slides.  
In NAFLD, inflammation in the lobules (lobular inflammation) and/or in portal 
tracts (portal inflammation) are known to occur. The latter is usually non-existent or mild 
(Brunt, 2001). A key characteristic of lobular inflammation is presence of mixed immune 
cells such as lymphocytes, macrophages, Kupffer cells and mostly polymorphonuclear 
leukocytes (PMN) (Brunt, 2004). The presence of portal inflammation is not necessary 
for the diagnosis of NASH (Matteoni et al. 1999). Portal inflammation was graded by the 
first pathologist on a scale of 0 – 3, 0 for no portal inflammation, 1 for mild, 2 for 
moderate and 3 for severe. On the other hand the second pathologist gave the slides a 
score of 0 for none to minimal portal inflammation and 1 for greater than minimal portal 
inflammation. In this case it is very difficult to judge the threshold for minimal 
inflammatory changes in the portal area. Moreover, these grades might be affected by the 
personal bias of the respective pathologist leading to differences in diagnoses of the 
cases. For the grades for lobular inflammation, however, the pathologists used the same 
scale. According to both, a score of 1 was given when 1- 2 inflammatory foci were seen 
at 20X magnification, 2 for the presence of 2-4 foci and 3 for more than 4 foci. In spite of 
the same scale for lobular inflammation, variation was observed in the diagnosis between 
the two pathologists. This most likely reflects the subjective nature of the grading system. 
Ballooned or swelled hepatocytes have clear cytoplasm. Mallory’s hyaline formed 
from the cytoplasmic fragments is present due to severe cell injury (Hubscher, 2006). 
However, the mallory hyaline may or may not be seen. Therefore, the presence of 
 
69 
Mallory hyaline is not important for the diagnosis of steatohepatitis (Brunt, 2005). 
Ballooning normally affects liver cells in acinar zone 3 and is one of the most distinctive 
traits of the more progressed form of the fatty liver disease (Matteoni et al., 1999). 
According to the Brunt grading system (Brunt et al., 1999) used by the first pathologist, 
ballooning is graded based on the location and extent of affected cells. However, the 
Kleiner grading system (Kleiner et al., 2005) gives a score of either 1 or 2 based on the 
estimate of severity. The scores of the two pathologists were comparable for ballooning. 
However no statistical test could be performed to verify the inter observer agreement 
since the two grading scales were different.  
In summary, significant associations between weight and insulin resistance and 
occurrence of NAFLD in baboons could not be established. This lack of significance is 
most likely due to disparity in the diagnoses of the two pathologists and/or sample size. 
Although baboons present the clinical and histological features of NAFLD similar to that 
seen in humans, future investigations with a much larger sample size will be required to 
capture the effect of weight, insulin resistance and dyslipidemia on the occurrence of 
fatty liver disease. This animal model may be helpful in understanding the underlying 
pathogenesis NAFLD since common environmental confounders such as alcohol 
consumption associated with human studies is not a problem. A secondary objective of 
subsequent research should be to validate the use of the liver biomarkers as a useful 
noninvasive tool for assessing NAFLD related liver damage in baboons. Future study 
should be done using liver slides made from fresh tissue samples. In this study some of 
the results may be artifacts due to the processing of frozen liver specimens. Finally, 
future projects should take into account the subjective nature of most grading systems 
 
70 
and use only one grading scale. The slides should be graded by the same pathologist 
twice, with the pathologist blind to the samples each time.  
In conclusion, this study provides evidence of occurrence of histological lesions 
similar to that seen in humans suffering from NAFLD. However, these histological 




TABLE 5.1 Grading system for non-alcoholic fatty liver disease (NAFLD) 
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Table 5.3 Histological features of non-alcoholic fatty liver disease observed in 


















   
< 33% 
 
36 10  
33-66% 
 
2 20 0.70 
> 66% 
 
1 9  
Ballooning 
 
   
None 
 










1 N/A  
Portal inflammation 
 
   
None to minimal 
 
22 30 0.11 
Greater than minimal 
 
17 9  
Lobular inflammation 
 
   
<2 foci per 20X field 
 
27 13  
2-4 foci per 20X field 
 
10 26 0.01 
> 4 foci per 20X field 
 
2 N/A  
 
*Pearson chi- square test between groups 
a






Table 5.4 Descriptive statistics of baboons with Non-alcoholic fatty liver disease 




*Mean (95 % confidence interval) 
a
Homeostasis model assessment method 
 
  
Category  1 
 
N = 35 
 
Category 2  
 






   
Male 
 
15 3  
Female 
 
20 1  
Age (yrs) 
 
15.7 (13.4,17.9)*   21.7 (18.4,24.9) 0.10 
Weight (kg) 
 
22.8(19.4,26.1)  34.9 (23.6,51.8)  0.06 
Alanine aminotransferase (IU/L) 
 
47.5 (39.5, 57.3) 43.2 (34.5, 54.0) 0.74 
Aspartate aminotransferase (IU/L) 
 
35.7 (30.4,42.0) 33.4 (28.4, 39.3) 0.79 
Gamma glutamyl transferase (IU/L) 
 
49.1 (44.9,53.7)  42.6 (38.1,47.5) 0.08 
Albumin (g/dl) 
 
4.6(4.4,4.9)  3.7(3.1,4.4)  0.009 
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Table 5.5 Descriptive statistics of baboons with non-alcoholic fatty liver disease 

























11 10  
Age (yrs) 
 
13 (10, 15.9)* 
 
19.1 (16.6, 21.6) 0.003 
Weight (kg) 
 
24.1 (19.9, 29.1) 23.6 (19.4, 28.6) 0.88 
Alanine aminotransferase (IU/L) 
 
46.4 (35.9, 59.9) 47.7 (37.9, 59.9) 0.88 
Aspartate aminotransferase (IU/L) 
 
35.5 (26.3, 47.8) 35.5 (32.1, 39.3) 0.99 
Gamma glutamyl transferase (IU/L) 
 
46.4 (40.7, 53) 50.2 (45.3, 55.6) 0.36 
Albumin (g/dl) 
 
4.7 (4.4, 5.1) 4.4 (4.1, 4.7) 0.13 
Hepatic Triglyceride content(mg/g) 
 





4.4 (2.7, 7.2) 3.0 (1.9, 4.7) 0.27 
 
*Mean (95 % confidence interval) 
a





















Figure 5.2 Category 1 of non-alcoholic fatty liver disease characterized by the 















































Figure 5.3  Category 2 of non-alcoholic fatty liver disease characterized by presence 
of steatosis, inflammation and ballooning (hematoxylin and eosin 40X) 
 
 







Conclusions and Recommendations 
 
This study shows the relationship between surrogate markers of non-alcoholic 
fatty liver (NAFLD) and adiposity related factors in baboons. The findings of this project 
suggest that reduced number of mature adipocytes in combination with inflammation 
may be involved in the pathogenesis of fatty liver disease associated with obesity and 
insulin resistance. A strong genetic influence on the adipocyte volume and number and 
circulating levels of liver function markers was observed in this project. A significant 
genetic correlation between liver proteins and adiposity and cardiovascular associated 
factors was also established. No significant relationship between the variations in liver 
function markers and various stages of NAFLD was found. Histological changes were 
observed independent of weight or insulin resistance status of the animals. 
Results from chapter 2 illustrate the association between circulating 
concentrations of MCP-1, adipocyte number, insulin resistance index (HOMA) and 
plasma levels of liver injury proteins. These relationships further strengthen the 
hypothesis that obesity related inflammation leads to reduced insulin sensitivity, which 
ultimately leads to fat deposition in the liver and raises the levels of liver related 
enzymes. Based on these findings the next step would be to explore the mechanism 
involved in the adipocyte dedifferentiation since very little research has been done in this 
area. Subsequent studies with a larger sample size should try to ascertain an association 
between insulin resistance and markers of fatty liver disease since impaired insulin 
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sensitivity is believed to the basis of this hepatic pathology. The drawbacks of this study 
were the use of a small sample and also lack of histological diagnosis of NAFLD using 
liver biopsies to establish the prevalence of hepatic lesions in these animals. 
In chapter 3 a substantial heritability for aspartate aminotransferase, a liver 
enzyme and omental adipocyte volume and number was estimated. A strong signal for fat 
cell volume (LOD score = 3.2) was located on baboon homologue of human chromosome 
6 at 73cM. The occurrence of linkage in this chromosomal region is of value since 
localization of other obesity related phenotypes in humans such as birth weight (Arya et 
al., 2006), body mass index (Atwood et al., 2006) and sum of skin folds (Duggirala et al., 
2001) also has been found on chromosome 6q. 
For the first time a significant genetic correlation between the physical 
characteristics of adipocytes and a biomarker of hepatic dysfunction was detected. These 
findings bolster the concept that reduced number of mature adipocytes could be 
responsible for the pathogenesis of co-morbitites related with increased adiposity. A 
future direction would be to identify the common set of genes and the pathways, which 
might influence fat cell volume and number and NAFLD. 
In this study we could not identify the QTLs for adipocyte number and AST. This 
might be due to the sample size which reduces the power to detect the loci for a trait of 
interest. Therefore this study should be done again with a substantially large number of 
baboons to obtain a significant QTL for adipocyte number and AST.  
Chapter 4 elucidates the results of the genome wide scan for plasma 
concentrations of γ glutamyl transferase (GGT) and albumin (ALB). A linkage for GGT 
was located on baboon homologue of human chromosome 22 (LOD = 2.8). A QTL (LOD 
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=2.3) was detected on the baboon homologue of human chromosome 10 for ALB. These 
findings are notable, as other phenotypes that are linked with obesity also have been 
mapped to these chromosomes. For example, peaks for genes expressed in human 
visceral adipose tissue (Yang et al., 2002), percentage fat mass (Dong et al, 2003)) and 
BMI of moderately obese individuals (Bell et al., 2004) were found on chromosome 22 
and 10, respectively. Future research efforts should involve fine mapping the identified 
genome segments. The functional gene for GGT resides on chorosome 22 which may be 
sequenced and single nucleotide polymorphisms (SNPs) may be typed within this gene. 
These endeavors would help us to evaluate the affect of variation in this gene on obesity 
associated phenotypes.  
This study found significant genetic correlations between plasma albumin and 
cardiovascular risk factors such as total cholesterol, LDL cholesterol and triglycerides. 
These results suggest that a common pathogenic agent, plausibly oxidative stress, might 
be responsible for the occurrence of both the liver and heart dysfunction in the state of 
obesity. This project failed to identify a relationship between the GGT and cardiovascular 
related phenotypes. One of the reasons for this could be due to sample size, which limits 
the power of association. A larger sample may allow the detection of a significant 
correlation between these traits and aid in detection of a significant LOD score for 
genome wide scan using bivariate analyses. 
A major limitation of these first three studies is the unavailability of liver biopsies 
to determine the exact stage of NAFLD in the animals. In addition no other 
anthropometric measurements other than body weight were available to verify the degree 
of adiposity in baboons. Future studies should include information about percent body fat 
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for a more accurate estimate of weight gain. Another drawback of this study is the 
possibility of liver enzymes elevation due to undiagnosed pathological conditions. 
In chapter 5 associations of liver injury biomarkers with the severity of the 
disease in baboons was found to be conflicting between the reports of the two 
pathologists. Although the plasma levels of liver proteins increase in the event of a 
hepatic injury (Angulo P, 2002), there are reports that NAFLD may occur in patients, in 
spite of normal levels of liver damage indicators (Sanyal A, 2002). This discrepancy 
suggests that liver function markers are not the most reliable indicator of the extent of 
liver damage due to fatty liver disease.  
The major drawback of this study was the use of frozen liver tissues for the 
preparation of slides. Processing steps such as thawing and fixing old specimens may 
have compromised their structural integrity. The handling procedure may have created 
artifacts which could have affected the accuracy of the diagnosis. An ideal experiment 
would have been to include age- and sex-matched lean and obese baboons in the study. In 
this study there were more lean baboons than obese ones. Most importantly, two different 
pathologists graded the liver slides and there was no similarity between their diagnoses. 
This might be due to the differences in their area of expertise. The first pathologist was a 
practicing human medical doctor in Mexico City; whereas, the second pathologist was a 
veterinarian at Southwest Foundation for Biomedical Research in San Antonio, Texas.  
Body weight and insulin resistance did not influence the incidence of NAFLD in 
this group of animals. This might be due to the limited sample size and the dissimilar 
results of the two pathologists, which might have reduced the capacity to estimate 
significant relationships. However no trends exist. Although we found the prevalence of 
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NAFLD in lean baboons, it could be due to many reasons such as hepatic iron overload, 
starvation leading to rapid weight loss, and/or jejunal diverticulosis (Angulo, 2002). In 
this project presence of hepatitis C was the only exclusion criteria used. Future studies 
should employ more stringent screening protocols such as animals with history of rapid 
weight loss, hepatic iron overload or other gastrointestinal diseases should be excluded 
from the cohort. However, it is not believed that our baboons exhibited any of these 
problems. 
It is important to investigate the pathophysiology relating obesity, insulin 
resistance and inflammation and NAFLD in the primate. Future research efforts should 
focus on the exploring the contribution of oxidative stress to both fatty liver and 
cardiovascular diseases. It is also important to identify loci that affect the obesity-related 
traits and liver proteins. Subsequent endeavors must be concentrated on bivariate genome 
wide scans to identify the pleiotropic genes that affect the phenotype of interest. 
In summary, objective 1 identified that plasma levels of monocyte 
chemoattractant protein -1 are associated with adipocyte volume and number, HOMA 
and circulating levels of liver function markers in baboons. Objective 2 established that 
omental adipocyte volume and number and plasma levels of aspartate aminotransferase 
are highly heritable traits in baboons. A significant correlation between aspartate 
aminotransferase and adipocyte volume and number also was determined. Objective 3 
found a quantitative trait locus (QTLs) for circulating levels of γ glutamyl transferase and 
albumin along with strong bivariate relationships between albumin and cardiovascular-
related risk factors. However, objective 4 could not establish a conclusive influence of 
body weight and insulin resistance on the occurrence of NAFLD in baboons. 
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In conclusion, these investigations initially suggested that obesity related factors 
might lead to an elevation of liver function markers in baboons. These results of this 
dissertation implied that baboons could be used to study the pathology related to 
elevation of liver proteins due to obesity and insulin resistance. In addition, this animal 
may be a model for genetic studies due to the lack of environmental confounders present 
in human studies. Liver biopsy is the best tool to diagnose NAFLD in baboons since the 
whole spectrum of the disease may occur in spite of normal levels of liver biomarkers. 
However, in this study we used frozen liver samples obtained during necropsy rather than 
biopsy. Nonetheless the results obtained using frozen liver samples did not match the 
theory. Thus, we can not conclude that liver function markers are a good indicator of 





Quantitative Genetic Analysis 
 
This project has employed a maximum likelihood-based variance decomposition 
approach implemented in the computer program sequential oligogenic linkage analysis 
routinues (SOLAR) to conduct genetic analyses (Almasy& Blangero, 1998).Univariate 
analysis was conducted to determine the heritability 
Quantitative genetic analysis estimates the effect of heritability on the variance of a 
trait (Comuzzie et al., 2001). This procedure is used to identify specific genes whose 
influence on a phenotype is quantifiable. It bifurcates total phenotypic variance in a trait 
(σP
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). The second 
component, the environmental element, is further segregated into assessable fractions 
such as housing, physical activity and immeasurable fractions (Falconer &Mackay, 
1996). 
The additive genetic effect is genetic variance due to the summation of the influence of 
all individual alleles that affect a trait. Dominance is defined as the genetic variance at a 
single locus due to dominance of one allele over another. Epistasis is when the 
phenotypic outcome of alleles of one gene is masked by alleles of another gene (Griffiths 
et al., 2000).  
The heritability (h
2
) of a trait is defined in two ways:  
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1) The proportion of phenotypic variance due to all genetic effects (additive, 
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Heritability is derived from a likelihood ratio test. This test compares the likelihood of a 
model whose heritability is estimated with the likelihood of a model whose heritability is 
confined to zero. Twice the difference of the logarithmic likelihood is distributed 
asymptotically as a ½: ½ mixture of a chi-square variable with one degree of freedom and 
a point mass at zero (Self & Liang, 1987). 
Genome wide scan is a method that identifies genes that may influence a trait. 
This approach does not speculate about the relevance of a gene or the chromosomal 
region; instead it searches for variation over the entire genome (Comuzzie et al., 2001). 
The genome scan output validates a candidate chromosomal region and/or a positional 
candidate gene (Almasy et al., 1999). A positional candidate gene is deemed important 
only if it is close to a QTL. A QTL detected through linkage analysis while conducting a 
genome wide scan that discerns polymorphisms distributed throughout the chromosome. 
A QTL may be defined as any locus that influences the variability in a quantifiable 
phenotype (Rogers et al., 1999). 
The variance component method is used to conduct linkage analysis. According to 
this technique population wide variance in a trait is due to genetic and non-genetic 
agents. Relationship between traits of family members can be addressed by dividing the 
agents that cause variance into i) a QTL associated with a chromosomal marker, 
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 ii) QTLs not related to the segment of interest, and iii) shared and individual 
environmental factors (Comuzzie et al. 2001). 
The concept of identity by descent (IBD) is the basis for linkage analysis. 
According to IBD two alleles at a locus are identical by descent if they are inherited from 
a single common ancestor without any new mutation 
 
(Rogers et al., 1999). Sharing of an 
IBD allele provides information about linkage. The expected IBD sharing between two 
related individuals is twice the kinship (Φ). Kinship is the probability of two genes from 
the same chromosomal loci selected from two individuals to be identical by descent. 
The variance elements can be computed by modeling covariance among members of the 
same ancestry: 
Ω = Π σ 2q + 2 Φσ
2
a + I σ
2
e 
Where Ω = covariance matrix for kindred 
Π = IBD matrix for related members at a specific marker 
σ 2q = additive genetic variance owing to a QTL associated to a marker 
Φ = kinship matrix 
σ2a = residual (non-genetic) additive variance  
I = identity matrix 
σ2e = environmental difference related to an individual 
The variance component model is implemented in the SOLAR program (Almasy 
and Blangero, 1999). The maximum likelihood method is used to verify the effect of a 
QTL. The null hypothesis, that additive genetic variance attributable to a QTL is zero is 
tested by comparing the likelihood of a model whose QTL is estimated with the 
likelihood of a model whose QTL is restricted to zero. This hypothesis testing generates a 
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logarithm of the odds (LOD). A LOD score of three or more is generally taken to be a 
strong predictor of the proximity between two loci. Twice the difference of the natural 
logarithmic likelihoods of these models is asymptotically distributed as a ½ : ½ mixture 
of chi-sqaure distribution with one degree of freedom (Self & Liang, 1987).  
Bivariate genetic analysis was employed to examine the genetic correlations between two 
phenotypes. Genetic relationship is the degree of pleiotropy or the percentage of genes 
shared by two quantifiable characteristics. In other words, genetic correlation is an 
estimate of the proportion of shared genes common to both traits. A bivariate phenotype 
may be due to a person’s measurable phenotype, population average, additive genetic 
effects and environmental consequences. A 2 × 2 covariance matrix provides the 
phenotypic covariance which is defined by the following equation:- 
Ωab = 2ΦρGσgaσgb + IρEσeaσeb, 
where a and b assume the values of 1 or 2, and ρG and ρE are the additive genetic and 
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